Sorafenib in advanced hepatocellular carcinoma

Llovet, Josep M., Ricci, Sergio, Mazzaferro, Vincenzo, Hilgard, Philip, Gane, Edward, Blanc, Jean-Frédéric, de Oliveira, Andre Cosme, Santoro, Armando +16 more·2008·New England Journal of Medicine

DOI 10.1056/nejmoa0708857

Cited by (1,037)

Items 801–900 of 1,037

Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
Richard Jackson, Eftychia‐Eirini Psarelli, Sarah Berhane, Harun Khan, Philip James Johnson · 2017 · Journal of Clinical Oncology
The role of autophagy in hepatocellular carcinoma: friend or foe
Lian Liu, Jiazhi Liao, Xingxing He, Peiyuan Li · 2017 · Oncotarget
Hypoxia inducible factors in hepatocellular carcinoma
Chu Chen, Tao Lou · 2017 · Oncotarget
JAK/STAT signaling in hepatocellular carcinoma
Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh · 2020 · Hepatic Oncology
Hepatic Stellate Cells and Hepatocarcinogenesis
Anna E. Barry, Rajkumar Baldeosingh, Ryan J. Lamm, Keyur Patel, Kai Zhang, Dana A. Dominguez, Kayla J. Kirton, Ashesh P. Shah, Hien T. Dang · 2020 · Frontiers in Cell and Developmental Biology
Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma
Xiufeng Zheng, Xun Liu, Yanna Lei, Gang Wang, Ming Liu · 2022 · Frontiers in Oncology
Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR)
European Society of Radiology (ESR) · 2015 · Insights into Imaging
The burden of illness associated with hepatocellular carcinoma in the United States
Kathleen Lang, Natalya Danchenko, Kathleen Gondek, Sonalee Shah, David Alan Thompson · 2008 · Journal of Hepatology
Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times
Khairuddin Memon, Laura Kulik, Robert J. Lewandowski, Edward Wang, Ahsun Riaz, Robert K. Ryu, Kent T. Sato, Karen Marshall, Ramona Gupta, Paul Nikolaidis et al. · 2011 · Gastroenterology
Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication
Minjong Lee · 2015 · World Journal of Biological Chemistry
MicroRNA‐125b attenuates epithelial‐mesenchymal transitions and targets stem‐like liver cancer cells through small mothers against decapentaplegic 2 and 4
Junnian Zhou, Quan Zeng, Haiyang Wang, Biao Zhang, Si‐Ting Li, Xue Nan, Ning Cao, Chunjiang Fu, Xinlong Yan, Yi Jia et al. · 2015 · Hepatology
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study
Carlo Sposito, Luigi Mariani, Alessandro Germini, Maria Flores Reyes, Marco Angelo Bongini, Glenda Grossi, Sherrie Bhoori, Vincenzo Mazzaferro · 2013 · Journal of Hepatology
Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90
W. Y. Lau, Bruno Sangro, Pei‐Jer Chen, Shu-Qun Cheng, Pierce K. H. Chow, Rheun‐Chuan Lee, Thomas W. T. Leung, Kwang‐Hyub Han, Ronnie T. P. Poon · 2013 · Oncology
Chemoembolization for Hepatocellular Carcinoma: Comprehensive Imaging and Survival Analysis in a 172-Patient Cohort
Robert J. Lewandowski, Mary F. Mulcahy, Laura Kulik, Ahsun Riaz, Robert K. Ryu, Talia Baker, Saad Ibrahim, Michael I. Abecassis, Frank H. Miller, Kent T. Sato et al. · 2010 · Radiology
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
Tiziana Pressiani, Corrado Boni, Lorenza Rimassa, Roberto Labianca, Stefano FAGIUOLI, Stefania Salvagni, D. Ferrari, Enrico Cortesi, Camillo Porta, Claudia Mucciarini et al. · 2012 · Annals of Oncology
Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy
Ron Charles Gaba, Ryan Peter Lokken, Ryan Hickey, Andrew J. Lipnik, Robert J. Lewandowski, Riad Salem, Daniel B. Brown, T. Gregory Walker, James Eric Silberzweig, Mark Otto Baerlocher et al. · 2017 · Journal of Vascular and Interventional Radiology
Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma
Mark M. Yarchoan, Parul Agarwal, Augusto Villanueva, Shuyun Rao, Laura A. Dawson, Thomas Benjamin Karasic, Josep Maria Llovet, Richard S. Finn, John D. Groopman, Hashem B. El‐Serag et al. · 2019 · Cancer Research
Recent advances in the management of hepatocellular carcinoma
K. Nathan Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew Eugene Hendifar, Ekaterina K. Koltsova, Ju Dong Yang · 2023 · Clinical and Molecular Hepatology
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial
Lorenza Rimassa, Armando Santoro · 2009 · Expert Review of Anticancer Therapy
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
K-F Chen, C-Y Liu, Y-C Lin, H-C Yu, T-H Liu, D-R Hou, P-J Chen, A-L Cheng · 2010 · Oncogene
Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma
Derek Lee, Mingjing Xu, David Kung‐Chun Chiu, Robin Kit‐Ho Lai, Aki Pui‐Wah Tse, Lynna Lan Li, Cheuk‐Ting Law, Felice Ho‐Ching Tsang, Larry Lai Wei, Cerise Yuen‐Ki Chan et al. · 2017 · Journal of Clinical Investigation
Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis
Yanchun Li, Jun Xia, Fangchun Shao, Yan Zhou, Jiaqi Yu, Hengyu Wu, Jing Du, Xueying Ren · 2020 · Biochemical and Biophysical Research Communications
Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy
Shwu-Huey Liu, Yung‐Chi Cheng · 2012 · Journal of Ethnopharmacology
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
Jeong Heo, Caroline J. Breitbach, Anne Moon, Chang Won Kim, Rick Patt, Mi Kyung Kim, Yu Kyung Lee, Sung Yong Oh, Hyun Young Woo, Kelley A. Parato et al. · 2011 · Molecular Therapy
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
Chun‐Jen Liu, Po‐Huang Lee, Deng‐Yn Lin, Cheng-Chung Wu, Long‐Bin Jeng, Pin-Wen Lin, King‐Tong Mok, Wei‐Chen Lee, Hong‐Zen Yeh, Ming‐Chih Ho et al. · 2009 · Journal of Hepatology
Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond
Kriti Mittal, John M.L. Ebos, Brian I. Rini · 2014 · Seminars in Oncology
Rationally Combining Anti-VEGF Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma
Tai Hato, Andrew Xiuxuan Zhu, Dan Gabriel Duda · 2016 · Immunotherapy
Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma
Ian K. Lai, Srividya Swaminathan, Virginie Baylot, Adriane R. Mosley, Renumathy Dhanasekaran, Meital Gabay, Dean W. Felsher · 2018 · Journal for ImmunoTherapy of Cancer
Sigma‐1 receptor protects against ferroptosis in hepatocellular carcinoma cells
Tao Bai, Pengxu Lei, Hao Zhou, Ruopeng Liang, Rongtao Zhu, Weijie Wang, Lin Zhou, Yuling Sun · 2019 · Journal of Cellular and Molecular Medicine
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Haber, Philipp K., Castet, Florian, Torres-Martin, Miguel, Andreu-Oller, Carmen, Puigvehí, Marc, Miho, Maeda, Radu, Pompilia, Dufour, Jean-Francois, Verslype, Chris, Zimpel, Carolin et al. · 2023 · Gastroenterology
Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”
Eleonora Terzi, Rita Golfieri, Fabio Piscaglia, M. Galassi, A. Dazzi, Simona Leoni, Emanuela Giampalma, Matteo Renzulli, Luigi Bolondi · 2012 · Journal of Hepatology
The Bcl-Xl Inhibitor, ABT-737, Efficiently Induces Apoptosis and Suppresses Growth of Hepatoma Cells in Combination with Sorafenib
Hayato Hikita, Tetsuo Takehara, Satoshi Shimizu, Takahiro Kodama, Minoru Shigekawa, Kyoko Iwase, Atsushi Hosui, Takuya Miyagi, Tomohide Tatsumi, Hisashi Ishida et al. · 2010 · Hepatology
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
Tokuzo Arao, Kazuomi Ueshima, KAZUKO Y. MATSUMOTO, Tomoyuki Nagai, Hideharu Kimura, Satoru Hagiwara, Toshiharu Sakurai, Seiji Haji, Akishige Kanazawa, Hisashi Hidaka et al. · 2012 · Hepatology
Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis
Alessandro Granito, Luigi Bolondi · 2017 · The Lancet Oncology
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
Jean‐Luc Raoul, Masatoshi Kudo, Richard S. Finn, Julien Edeline, María Reig, Peter R. Galle · 2018 · Cancer Treatment Reviews
Neuropilins: expression and roles in the epithelium
Jonathan R. L. Wild, Carolyn A. Staton, Keith S. Chapple, Bernard Michael Corfe · 2012 · International Journal of Experimental Pathology
Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis
Mian Xi, Li Zhang, Lei Zhao, Qiao-Qiao Li, Su-Ping Guo, Zizhen Feng, Xiao-Wu Deng, Xiao-Yan Huang, Mengzhong Liu · 2013 · PLoS ONE
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis
Do Seon Song, Myeong Jun Song, Si Hyun Bae, Woo Jin Chung, Jae Young Jang, Young Seok Kim, Sae Hwan Lee, Jun Yong Park, Hyung Joon Yim, Sung Bum Cho et al. · 2014 · Journal of Gastroenterology
Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
Zheng-Gang Ren, Kang-Shun Zhu, HaiYan Kang, Min-qiang Lu, Zengqiang Qu, Ligong Lu, Tian-Qiang Song, Wei-Ping Zhou, Hui Wang, WeiZhu Yang et al. · 2015 · Journal of Clinical Oncology
Antiangiogenic therapy—evolving view based on clinical trial results
Gordon C. Jayson, Daniel J. Hicklin, Lee M. Ellis · 2012 · Nature Reviews Clinical Oncology
Acetyl‐coenzyme A carboxylase alpha promotion of glucose‐mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients
Ming‐Da Wang, Han Wu, Gongbo Fu, Hui‐Lu Zhang, Xu Zhou, Liang Tang, Liwei Dong, Chen‐Jie Qin, Shuai Huang, Ling‐Hao Zhao et al. · 2015 · Hepatology
Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation
Caroline I. Davis, Xingxing Gu, Ryan M. Kiefer, Martina Ralle, Terence P.F. Gade, Donita C. Brady · 2020 · Metallomics
Sorafenib: a clinical and pharmacologic review
Iyer, Renuka, Fetterly, Gerald, Lugade, Amit, Thanavala, Yasmin · 2010 · Expert Opinion on Pharmacotherapy
OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma
Akihisa Ueno, Yohei Masugi, Ken Yamazaki, Mina Komuta, Kathryn Effendi, Yutaka Tanami, Hanako Tsujikawa, Akihiro Tanimoto, Shigeo Okuda, Osamu Itano et al. · 2014 · Journal of Hepatology
Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan
the Liver Cancer Study Group of Japan, Kazuhiro Nouso, Koji Miyahara, D Uchida, Kenji Kuwaki, Namiki Izumi, Masao Omata, Takafumi Ichida, Masatoshi Kudo, Yonson Ku et al. · 2013 · British Journal of Cancer
Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
Elizabeth Allen, Ian B Walters, Douglas Hanahan · 2011 · Clinical Cancer Research
hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma Therapy
Eran Elyakim, Einat Sitbon, Alexander Faerman, Sarit Tabak, Eve Montia, Liron Belanis, Avital Dov, Eric G. Marcusson, C. Frank Bennett, Ayelet Chajut et al. · 2010 · Cancer Research
RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Shukui Qin, Richard S. Finn, Masatoshi Kudo, Tim Meyer, Arndt Vogel, Michel Pierre Ducreux, Teresa Mercade Macarulla, Gianluca Tomasello, Frédéric Boisserie, Jeannie Whit-Shan Hou et al. · 2019 · Future Oncology
MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma
Stefanie J. C. G. Hectors, Sara C. Lewis, Cecilia Besa, Michael J. King, Daniela Said, Juan Putra, Stephen C. Ward, Takaaki Higashi, Swan N. Thung, Yao Shen et al. · 2020 · European Radiology
Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma
Xiaolin Wu, Jiahui Li, Asmae Gassa, Denise Buchner, Hakan Alakus, Qiongzhu Dong, Ning Ren, Ming Liu, Margarete Odenthal, Dirk Ludger Stippel et al. · 2020 · International Journal of Biological Sciences
Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity
Loraine Kay D. Cabral, Claudio Tiribelli, Caecilia Hapsari Ceriapuri Sukowati · 2020 · Cancers
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
Kohei Shigeta, Aya Matsui, Hiroto Kikuchi, Sebastian Klein, Émilie Mamessier, Ivy X. Chen, Shuichi Aoki, Shuji Kitahara, Koetsu Inoue, Ayako Shigeta et al. · 2020 · Journal for ImmunoTherapy of Cancer
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic–pathologic correlation
Ahsun Riaz, Khairuddin Memon, Frank H. Miller, Paul Nikolaidis, Laura Kulik, Robert J. Lewandowski, Robert K. Ryu, Kent T. Sato, Vanessa L. Gates, Mary F. Mulcahy et al. · 2010 · Journal of Hepatology
Targeting immune suppressing myeloid-derived suppressor cells in oncology
Johnny Kao, Eric C. Ko, Samuel G. Eisenstein, Andrew Gregory Sikora, Shibo Fu, Shu‐Hsia Chen · 2010 · Critical Reviews in Oncology/Hematology
Treatment of Intermediate/Advanced Hepatocellular Carcinoma in the Clinic: How Can Outcomes Be Improved?
Riccardo Antonio Lencioni, Xiaoping Chen, Lucy Dagher, Alan Paul Venook · 2010 · The Oncologist
Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses
Gwang Hyeon Choi, Ju Hyun Shim, Min-Joo Kim, Min‐Hee Ryu, Baek‐Yeol Ryoo, Yoon‐Koo Kang, Yong Moon Shin, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee · 2013 · Radiology
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
Philip C. De Witt Hamer · 2010 · Neuro-Oncology
The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma
Wei-Wei Zhai, T. Lim, Tong Zhang, S. Phang, Z. Tiang, P. Guan, M. Ng, Jia-Qi Lim, Fei Yao, Zheng Li et al. · 2017 · Nature Communications
Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine
Xie, Feihu, Sun, Lejia, Pang, Yuan, Xu, Gang, Jin, Bao, Xu, Haifeng, Lu, Xin, Xu, Yiyao, Du, Shunda, Wang, Yanan et al. · 2021 · Biomaterials
Sorafenib inhibits the shedding of major histocompatibility complex class I–related chain A on hepatocellular carcinoma cells by down‐regulating a disintegrin and metalloproteinase 9†
Keisuke Kohga, Tetsuo Takehara, Tomohide Tatsumi, Hisashi Ishida, Takuya Miyagi, Atsushi Hosui, Norio Hayashi · 2009 · Hepatology
Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis
Marcus‐Alexander Wörns, Arndt Weinmann, Kerstin Pfingst, Carla Schulte-Sasse, Claudia‐Martina Messow, Henning Schulze‐Bergkamen, Andreas Teufel, Marcus Schuchmann, Stephan Kanzler, Christoph Düber et al. · 2009 · Journal of Clinical Gastroenterology
Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy
Zhe Zhang, Xiaoyun Zhou, Hujia Shen, Dexing Wang, Yanhong Wang · 2009 · BMC Medicine
Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma
Jian‐Hong Fang, Li Xu, Li‐Ru Shang, C. Pan, Jin Ding, Yunqiang Tang, Hui Liu, Chu-Xing Liu, Jia‐Lin Zheng, Yaojun Zhang et al. · 2018 · Hepatology
Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation
Norma Arteiro Filgueira · 2019 · World Journal of Hepatology
Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells
Bin Sun, Dong Yang, Hongjiu Dai, Xiuyun Liu, Ru Jia, Xiaoyue Cui, Wenxuan Li, Changchun Cai, Jianming Xu, Xudong Zhao · 2019 · Cancer Immunology Research
Endothelial cells in tumor microenvironment: insights and perspectives
Patrizia Leone, Eleonora Malerba, Nicola Susca, Elvira Favoino, Federico Perosa, Giuliano Brunori, Marcella Prete, Vito Racanelli · 2024 · Frontiers in Immunology
Emerging Trends in Hepatocellular Carcinoma: Focus on Diagnosis and Therapeutics
Avegail G. Flores, Jorge A. Marrero · 2014 · Clinical Medicine Insights Oncology
How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective
Jean‐Luc Raoul, Marine Gilabert, Gilles Piana · 2014 · Liver Cancer
Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan
Masatoshi Kudo, Namiki Izumi, Michiie Sakamoto, Yutaka Matsuyama, Takafumi Ichida, Osamu Nakashima, Osamu Matsui, Yonson Ku, Norihiro Kokudo, Masatoshi Makuuchi et al. · 2016 · Liver Cancer
Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion
Carlo Spreafico, Carlo Sposito, Marta Vaiani, Tommaso Cascella, Sherrie Bhoori, Carlo Morosi, Rodolfo Lanocita, Raffaele Romito, Carlo Chiesa, Marco Maccauro et al. · 2018 · Journal of Hepatology
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas
Cindy Neuzillet, Armand D.E. Gramont, Annemilaï Tijeras‐Raballand, Louis de Mestier, Jerome F. Cros, Sandrine J. Faivre, Éric Raymond · 2013 · Oncotarget
PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus–Induced Liver Carcinogenesis
Hao Zhang, Ahmed Diab, Huitao Fan, Saravana Kumar Kailasam Mani, Ronald Loral Hullinger, Philippe Merle, OURANIA M. ANDRISANI · 2015 · Cancer Research
miR-490-3p Modulates Cell Growth and Epithelial to Mesenchymal Transition of Hepatocellular Carcinoma Cells by Targeting Endoplasmic Reticulum-Golgi Intermediate Compartment Protein 3 (ERGIC3)
Lingyun Zhang, Min Liu, Xin Li, Hua Tang · 2012 · Journal of Biological Chemistry
Regorafenib for cancer
Dirk Strumberg, Beate S. Schultheis · 2012 · Expert Opinion on Investigational Drugs
Infiltrative Hepatocellular Carcinoma: What Radiologists Need to Know
Arich R. Reynolds, Alessandro Furlan, David T. Fetzer, Eizaburo Sasatomi, Amir Ali Borhani, Matthew T. Heller, MITCHELL E. TUBLIN · 2015 · Radiographics
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma
Min Li, Weiyue Zhang, Birong Wang, Yang Gao, Zifang Song, Qi Zheng · 2016 · International Journal of Nanomedicine
Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in hepatocellular carcinoma: A novel link between oxidative stress and cancer
Huiqin Zhong, Mengqing Xiao, Kamelija Žarković, Mingjiang Zhu, Rina Sa, Jianhong Lu, Yongzhen Tao, Qun Chen, Lin Xia, Shuqun Cheng et al. · 2016 · Free Radical Biology and Medicine
Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment
Fabio Piscaglia, Sadahisa Ogasawara · 2018 · Liver Cancer
Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma
Clifford Akateh, Sylvester M. Black, Lanla F. Conteh, Eric David Miller, Anne M. Noonan, Eric D. Elliott, Timothy Michael Pawlik, Allan Tsung, Jordan M. Cloyd · 2019 · World Journal of Gastroenterology
Imaging biomarkers for evaluating tumor response: RECIST and beyond
Ching‐Chung Ko, Lee‐Ren Yeh, Yu‐Ting Kuo, Jeon‐Hor Chen · 2021 · Biomarker Research
Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD
Simon Wabitsch, Justin McCallen, Olena Kamenyeva, Benjamin Ruf, John C. McVey, Juraj Kabát, Juliane S. Walz, Yaron Rotman, Kylynda C. Bauer, Amanda J. Craig et al. · 2022 · Journal of Hepatology
Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Joong‐Won Park, Richard S. Finn, Jun Suk Kim, Mark Karwal, Ruby K. Li, Fuad Ismail, Melanie B. Thomas, Rosemarie Harris, Christine Baudelet, Ian B Walters et al. · 2011 · Clinical Cancer Research
Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?
Allard, Marc-Antoine, Sebagh, Mylène, Ruiz, Aldrick, Guettier, Catherine, Paule, Bernard, Vibert, Eric, Cunha, Antonio Sa, Cherqui, Daniel, Samuel, Didier, Bismuth, Henri et al. · 2015 · Journal of Hepatology
Interleukin-6: An angiogenic target in solid tumours
Kathryn Middleton, Joanna E. Jones, Zarnie Lwin, Jermaine Ian George Coward · 2013 · Critical Reviews in Oncology/Hematology
Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
Bert H. O’Neil, Laura Williams Goff, John Sae Wook Kauh, Jonathan Strosberg, Tanios Bekaii‐Saab, Ruey-min Lee, Aslamuzzaman Kazi, Dominic T. Moore, Maria Learoyd, Richard M. Lush et al. · 2011 · Journal of Clinical Oncology
Inflammation- and stress-related signaling pathways in hepatocarcinogenesis
Hayato Nakagawa · 2012 · World Journal of Gastroenterology
Expression of Slc22a1 Variants May Affect the Response of Hepatocellular Carcinoma And Cholangiocarcinoma To Sorafenib
Elisa Herráez, Elisa Lozano, Rocı́o I.R. Macı́as, Javier Vaquero, Luís Bujanda, Jesús M. Bañales, José J.G. Marı́n, Óscar Briz · 2013 · Hepatology
Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization
Elias Björnson, Bani Mukhopadhyay, Anna Asplund, Nuša Pristovšek, Reşat Çınar, Stefano Romeo, Mathias Uhlén, George Kunos, Jens Nielsen, Adil Mardinoğlu · 2015 · Cell Reports
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Masatoshi Kudo · 2019 · World Journal of Gastroenterology
Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis
Mengzhou Guo, Feifei Yuan, Feng Qi, Jialei Sun, Qianwen Rao, Zhiying Zhao, Peixin Huang, Tingting Fang, Biwei Yang, Jinglin Xia · 2020 · Journal of Translational Medicine
Phase 2 open‐label study of single‐agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B–endemic Asian population
Thomas C. C. Yau, Pierre Chan, Kelvin K. Ng, Ksh Chok, Tan To Cheung, Sheung Tat Fan, Ronnie T. P. Poon · 2008 · Cancer
Management of hepatocellular carcinoma with portal vein thrombosis
Matthew Quirk · 2015 · World Journal of Gastroenterology
Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma
Patrick P. McHugh, Jeffrey Gilbert, SANTIAGO R. VERA, Alvaro Koch, Dinesh Ranjan, Roberto Gedaly · 2010 · HPB
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
Dali Zhao, Bo Zhai, Changjun He, Gang Tan, Xian Li Jiang, Shangha Pan, Xuesong Dong, Zheng Wei, Lixin Ma, Haiquan Qiao et al. · 2014 · Cellular Signalling
Blockade of store-operated Ca2+ entry inhibits hepatocarcinoma cell migration and invasion by regulating focal adhesion turnover
Ning Yang, Ying Fei Tang, Fang Wang, Haibin Zhang, Dan Xu, Yafeng Shen, Shuhan Sun, Guang-Shun Yang · 2012 · Cancer Letters
Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma
Yuanyuan Ruan, Linlin Sun, Yuqing Hao, Lijing Wang, Jiejie Xu, Wen Zhang, Jianhui Xie, Liang Guo, Lei Zhou, Xiaojing Yun et al. · 2012 · Journal of Clinical Investigation
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
Beverly L. Falcón, Sudhakar R. Chintharlapalli, Mark T. Uhlik, Bronislaw Pytowski · 2016 · Pharmacology & Therapeutics
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine J. Faivre, Armando Santoro, Robin Kate Kelley, Ed J. Gane, Charlotte E. Costentin, Ivelina Gueorguieva, Claire L. Smith, Ann Cleverly, Michael Lahn, Éric Raymond et al. · 2019 · Liver International
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
Christo Kole, Nikolaos Charalampakis, Sergios A. Tsakatikas, Michail G. Vailas, Dimitrios Moris, Efthymios Gkotsis, Stylianos Kykalos, Michalis V. Karamouzis, Dimitriοs Schizas · 2020 · Cancers
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study
Xiaoyan Ding, Wei Sun, Wei Li, Yanjun Shen, Xiaodi Guo, Ying Teng, Xiaomin Liu, Linlin Zheng, Wendong Li, Jinglong Chen · 2021 · Cancer